| Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. | |
| | |
MedLine Citation:
|
PMID: 10090928 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
It is debated whether follicular large cell lymphoma (FLCL) has a clinical behavior that is distinct from indolent follicular lymphomas, and whether there is a subset of patients who can be potentially cured. We report here our experience with 100 FLCL patients treated at our institution since 1984 with three successive programs. We evaluated the predictive value of pretreatment clinical features, including two risk models, the Tumor Score System and the International Prognostic Index (IPI). With a median follow-up of 67 months, the 5-year survival is 72% and the failure-free survival (FFS) is 67%, with a possible plateau in the FFS curve, particularly for patients with stage I-III disease. Features associated with shorter survival included age >/=60, elevated lactic dehydrogenase (LDH) or beta-2-microglobulin (beta2M), advanced stage, and bone marrow involvement. Stage III patients had significantly better survival than stage IV patients (P <.05). By the IPI and Tumor Score System, 80% of the patients were in the lower risk groups; both systems stratified patients into prognostic groups. Patients with FLCL have clinical features and response to treatment similar to that reported for diffuse large cell lymphoma. Prognostic risk systems for aggressive lymphomas are useful for FLCL. A meaningful fraction of patients may possibly be cured when treated as aggressive lymphomas. |
| | |
Authors:
|
J Rodriguez; P McLaughlin; F B Hagemeister; L Fayad; M A Rodriguez; M Santiago; M Hess; J Romaguera; F Cabanillas |
Related Documents
:
|
16166588 - Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with n... 482588 - Angio-immunoblastic lymphadenopathy: report of ten cases and review of the literature. 2224798 - Diffuse intermediate lymphocytic lymphoma. a clinicopathologic study and comparison wit... 17940628 - Aggressive burkitt-like lymphoma of colon in a patient with prior celiac disease. 23013138 - Markers of circulating tumour cells in the peripheral blood of melanoma patients correl... 11173148 - Prognostic factor studies in oncology: osteosarcoma as a clinical example. |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Blood Volume: 93 ISSN: 0006-4971 ISO Abbreviation: Blood Publication Date: 1999 Apr |
Date Detail:
|
Created Date: 1999-04-19 Completed Date: 1999-04-19 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7603509 Medline TA: Blood Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 2202-7 Citation Subset: AIM; IM |
Affiliation:
|
University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antibiotics, Antineoplastic / administration & dosage Antineoplastic Agents, Alkylating / administration & dosage Antineoplastic Combined Chemotherapy Protocols / therapeutic use Bleomycin / administration & dosage Cyclophosphamide / administration & dosage Cytarabine / administration & dosage Disease-Free Survival Doxorubicin / administration & dosage Etoposide / administration & dosage Female Follow-Up Studies Humans Ifosfamide / administration & dosage Lymphoma, Follicular / drug therapy, mortality*, pathology Lymphoma, Non-Hodgkin / drug therapy, mortality*, pathology Male Middle Aged Mitoxantrone / administration & dosage Neoplasm Staging Prednisone / administration & dosage Prognosis Risk Factors Severity of Illness Index Survival Analysis Vincristine / administration & dosage |
| Grant Support | |
ID/Acronym/Agency:
|
CA16672/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibiotics, Antineoplastic; 0/Antineoplastic Agents, Alkylating; 0/CHOP-B protocol; 0/OPEN protocol; 11056-06-7/Bleomycin; 147-94-4/Cytarabine; 23214-92-8/Doxorubicin; 33419-42-0/Etoposide; 3778-73-2/Ifosfamide; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine; 65271-80-9/Mitoxantrone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with bu...
Next Document: Development of viral vectors for gene therapy of beta-chain hemoglobinopathies: optimization of a ga...